| Literature DB >> 20516078 |
Patricia Bernal1, Sandrine Lemaire, Mariana G Pinho, Shahriar Mobashery, Jason Hinds, Peter W Taylor.
Abstract
Epicatechin gallate (ECg) sensitizes methicillin-resistant Staphylococcus aureus (MRSA) to oxacillin and other beta-lactam agents; it also reduces the secretion of virulence-associated proteins, prevents biofilm formation, and induces gross morphological changes in MRSA cells without compromising the growth rate. MRSA is resistant to oxacillin because of the presence of penicillin-binding protein 2a (PBP2a), which allows peptidoglycan synthesis to continue after oxacillin-mediated acylation of native PBPs. We show that ECg binds predominantly to the cytoplasmic membrane (CM), initially decreasing the fluidity of the bilayer, and induces changes in gene expression indicative of an attempt to preserve and repair a compromised cell wall. On further incubation, the CM is reorganized; the amount of lysylphosphatidylglycerol is markedly reduced, with a concomitant increase in phosphatidylglycerol, and the proportion of branched chain fatty acids increases, resulting in a more fluid structure. We found no evidence that ECg modulates the enzymatic activity of PBP2a through direct binding to the protein but determined that PBP2 is delocalized from the FtsZ-anchored cell wall biosynthetic machinery at the septal division site following intercalation into the CM. We argue that many features of the ECg-induced phenotype can be explained by changes in the fluid dynamics of the CM.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20516078 PMCID: PMC2911331 DOI: 10.1074/jbc.M110.114793
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157
Genes with increased expression of at least 2-fold following exposure to ECg, compared with cell wall stress stimulon up-regulation determined in other studies
| MRSA252 | N315 | Gene | Product or putative function | ECg | VISA | Vancomycin | Oxacillin bacitracin | Daptomycin | Functional category |
|---|---|---|---|---|---|---|---|---|---|
| Homoserine kinase | 2.48 | Amino acid biosynthesis | |||||||
| Dihydropicolinate synthase | 2.66 | Amino acid biosynthesis | |||||||
| Threonine synthase | 3.06 | Amino acid biosynthesis | |||||||
| Homoserine dehydrogenase | 3.76 | Amino acid biosynthesis | |||||||
| Conserved hypothetical protein | 3.6 | Up | Carbohydrate transport and metabolism | ||||||
| Glycerate kinase | Up | 14.8 | Carbohydrate transport and metabolism | ||||||
| Reductase regulator | 4.8 | 2.5 | Transcription | ||||||
| Transcriptional regulator | 2.7 | 3.4 | 14 | Regulation/transcription | |||||
| Transcriptional regulator, MerR family | 2.18 | Regulatory functions | |||||||
| Response regulator | 2.5 | 8.7 | 10.39 | Signal transduction mechanism | |||||
| Sensor histidine kinase | 2.5 | 8.7 | 10.4 | 9.57 | Signal transduction mechanism | ||||
| Conserved hypothetical protein | 2.60 | 8.1 | 7.1 | Function unknown | |||||
| Hypothetical protein | 3.1 | Up | Function unknown | ||||||
| SAR0204 | SA0205 | Peptidase domain protein | 4.5 | Up | Cell envelope biogenesis | ||||
| SAR0273 | SA0265 | Peptidoglycan hydrolase | 4.8 | 2.2 | Cell envelope biogenesis | ||||
| Autolysis/methicillin resistance | Up | Up | 4.93 | Cell envelope biogenesis | |||||
| Transglycosylase domain protein | 2.9 | 10.6 | 8.10 | Cell envelope biogenesis | |||||
| Teichoic acid biosynthesis protein | 2.90 | Cell envelope biogenesis | |||||||
| TcaA protein | 4.1 | Up | 3.03 | Cell envelope | |||||
| Penicillin binding protein 2 | 2.21 | Cell envelope | |||||||
| UDP-GlcNAc-carboxytransferase | 4.14 | Cell envelope | |||||||
| Protease maturation protein | 3.2 | 12 | 7.7 | 9.59 | Protein turnover and chaperones | ||||
| Serine protease HtrA | 6.8 | 11 | 3.06 | Protein turnover and chaperones | |||||
| ATP-dependent Clp protease, ClpC | 3.98 | Protein turnover and chaperones | |||||||
| ATP-dependent Clp protease, CLpB | 3.87 | Protein turnover and chaperones | |||||||
| Heat shock protein GrpE | 3.28 | Protein folding and stabilization | |||||||
| Chaperonin, 10 kDa | 2.84 | Protein folding and stabilization | |||||||
| Chaperonin, 33 kDa | 2.15 | Protein folding and stabilization | |||||||
| Heat shock protein HslVU | 2.12 | Protein folding and stabilization | |||||||
| heat shock protein Hsp20 | 3.08 | Protein folding and stabilization | |||||||
| SAR2064 | SA1777 | Hypothetical protein | 2.3 | General function | |||||
| SAR2388 | SA2097 | Secretory antigen precursor | 4.8 | General function | |||||
| SAR0925 | SA0824 | Conserved hypothetical protein | 2.1 | 5.8 | Function unknown | ||||
| Choline dehydrogenase | Up | Cell motility and secretion | |||||||
| Type-1 signal peptidase 1B | 4.7 | Up | 2.56 | Cell motility and secretion | |||||
| Riboflavin biosynthesis protein | 2.9 | Coenzyme metabolism | |||||||
| SAR0580 | SA0533 | Long chain fatty acid CoA ligase | Lipid metabolism | ||||||
| SAR0581 | SA0534 | Acetyl-CoA acetyltransferase | Lipid metabolism | ||||||
| SAR0582 | SA0535 | Hypothetical protein | Function unknown | ||||||
| SAR0583 | SA0536 | Hypothetical protein | Function unknown | ||||||
| Hypothetical protein | 22.7 | 224.7 | 26.6 | Function unknown | |||||
| Hypothetical protein | 5.3 | Up | Up | Function unknown | |||||
| γ-Hemolysin, component A | 10.18 | Toxin production and resistance | |||||||
| drP35 | 8.87 | Toxin production and resistance | |||||||
| γ-Hemolysin, component B | 5.04 | Toxin production and resistance | |||||||
| g-Hemolysin, component C | 3.52 | Toxin production and resistance | |||||||
| Similar to chitinase B | 2.2 | 10.6 | 5.5 | ||||||
| SAR1730 | SA1476 | Hypothetical protein | 4 | 20.9 | |||||
| SAR1731 | SA1477 | Hypothetical protein | 5.2 | 27.6 | |||||
| Hypothetical protein | 2 | Up | Up | ||||||
| SAR2065 | SA1778 | Hypothetical protein | 2.2 | ||||||
| SAR2184 | SA1898 | SceD protein | 10.5 | ||||||
| SAR2407 | SA2113 | Hypothetical protein | 3.8 | 10.4 | |||||
| Hypothetical protein | 2.4 | 9.5 | 18.7 | ||||||
| Hypothetical protein | 84.4 | Up | Up | ||||||
| Hypothetical protein | Up | ||||||||
| Hypothetical protein | 3.4 | 5.7 | |||||||
| GTP-pyrophosphokinase | 2.0 | 8.6 | Up |
MRSA252 ORF identifiers for the BμG@S SAv1.1.0 microarray used in this study (30). ORF identifiers in bold form the genes of the core cell wall stress stimulon as defined by McAleese et al. (40).
N315 ORF identifiers for the S. aureus N315 microarray described by McAleese et al. (40). ORF identifiers in bold form the genes of the core cell wall stress stimulon as defined by McAleese et al. (40).
Data from this study with S. aureus EMRSA-16.
Up-regulation of cell wall stress stimulon genes induced by spontaneous mutation of a clinical S. aureus isolate to VISA and by exposure to suprainhibitory concentrations of vancomycin (40).
Up-regulated genes after exposure of S. aureus RN450 to these agents (38).
Up-regulated genes after exposure of S. aureus ATCC 29213 to suprainhibitory concentrations of daptomycin (41).
FIGURE 1.Membrane fluidity of MRSA-16 grown in the absence of ECg ( The fluorescent probe DPH was incorporated into the CM as described under “Experimental Procedures.” The bars represent the means ± S.D. (n = 15), and the levels of significance were determined using paired Student's t test.
FIGURE 2.Two-dimensional TLC analysis of membrane lipids extracted from MRSA-16 grown to mid-logarithmic phase ( The growth medium (MH broth) contained 18.5 KBq/ml of [32P]orthophosphate. The spots were visualized by autoradiography, and their intensity was quantified using a Bio-Rad Molecular Imager FX; the data are presented in the bottom panel. CL, cardiolipin; lysoPG, lysophosphatidylglycerol. The LPG total is the sum of values obtained from spots LPG and LPG-2. Each of the minor phospholipid components from ECg-free and ECg-containing cultures constituted less than 1% of total lipid extracted. The values given are the percentages of total lipid extracted ± S.D. (n = 9).
Fatty acid composition of phospholipids extracted from EMRSA-16 following growth to mid-logarithmic phase (grown to
| Fatty acid | MH broth | MH broth + ECg |
|---|---|---|
| C10:0 | 0.48 ± 0.07 | 0.65 ± 0.05 |
| C11:0 | 0.23 ± 0.04 | 0.39 ± 0.05 |
| C12:0 | 0.62 ± 0.07 | 0.54 ± 0.07 |
| 0.56 ± 0.07 | 0.65 ± 0.02 | |
| C14:0 | 8.19 ± 0.72 | 4.84 ± 0.50 |
| 2.33 ± 0.09 | 3.36 ± 0.30 | |
| 3.31 ± 0.15 | 4.82 ± 0.28 | |
| C15:0 | 3.27 ± 0.50 | 1.80 ± 0.05 |
| 0.86 ± 0.07 | 0.97 ± 0.06 | |
| C16:0 | 13.42 ± 0.44 | 13.84 ± 0.55 |
| 1.52 ± 0.03 | 2.09 ± 0.12 | |
| 2.25 ± 0.10 | 3.64 ± 0.08 | |
| C17:0 | 3.01 ± 0.17 | 2.32 ± 0.14 |
| C18:1,9 | 2.49 ± 0.46 | 3.92 ± 0.61 |
| C18:0 | 24.61 ± 1.34 | 28.09 ± 1.13 |
| 1.24 ± 0.10 | 1.57 ± 0.03 | |
| 0.95 ± 0.07 | 1.47 ± 0.17 | |
| C19:0 | 9.82 ± 0.30 | 7.35 ± 0.45 |
| C20:0 | 18.23 ± 1.79 | 14.91 ± 1.26 |
| C21:0 | 2.62 ± 0.18 | 2.78 ± 0.16 |
| % Branched (br) | 15.51 | 22.49 |
| % Non-branched (n-br) | 84.49 | 77.51 |
| Ratio (br/n-br) | 0.18 | 0.29 |
FIGURE 3.Location of PBP2 in MRSA strain COLpPBP2-31 as determined by fluorescence microscopy. This strain carries a gfp-pbp2 fusion. The bacteria were visualized after growth in MH broth (A) and in broth containing 4 μg/ml oxacillin (B), 12.5 μg/ml ECg (C), and 4 μg/ml oxacillin and 12.5 μg/ml ECg (D). The extent of localization of PBP2 at the septum was determined by calculating the ratio (a − c/b − c), where a stands for fluorescence found at the septum, b stands for fluorescence at the lateral membrane, and c stands for background fluorescence (E). The values are the means ± S.D. from measurement of fluorescence ratios of 200 cells in each sample. A ratio (a − c/b − c) greater than 2 indicates localization at the septum, where two membranes are present, whereas a ratio of 2 or less than two indicates delocalization (59).
FIGURE 4.Binding of the fluorescent penicillin derivative Bocillin FL to PBPs recovered from RUSA130 and exposed to 12.5 μg/ml ECg. This strain produces a truncated form of PBP2 and enables the detection of PBP2a, which migrates in gels in an identical fashion to native PBP2. After incubation with ECg, the samples were labeled with 25 μm Bocillin FL and separated by 10% SDS-PAGE, and the proteins were detected by fluorography. −, no ECg. Truncated PBP2 has very low affinity for β-lactam agents (29, 48) and does not bind sufficient Bocillin FL for visualization on the gel.
FIGURE 5.β-Lactam binding ( A, binding of the fluorescent penicillin derivative Bocillin FL to PBP2a (5 μm). PBP2a was incubated for up to 24 h in 12.5 μg/ml ECg. The samples were then incubated for 25 min in the presence of 1.25 μg of Bocillin FL and prepared for fluorescence measurement. The results were expressed as percentages of change from controls (no ECg added). The values are the means ± S.D. B, binding of increasing concentrations of Bocillin FL to PBP2a (5 μm). PBP2a was incubated over 1 h in 12.5 μg/ml ECg. Binding was then measured after 25 min in the presence of increasing concentrations of Bocillin FL. The values are the means ± S.D. C, tryptophan fluorescence emission spectra of PBP2a (0.18 μg/ml). The pretreatments of PBP2a are as follows: ECg added (1 h, 12.5 μg/ml) and denatured protein (1 h, 60 °C). We have previously determined (36) that the Bocillin FL concentrations employed in these experiments enable the detection of changes in the affinity of PBP2a for β-lactam antibiotics.